Loading…

Twenty years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice

Herpes Simplex Virus (HSV) is the most common virus that causes eye disease. Although around 60% of the world's population are seropositive for HSV antigens, fortunately, it is estimated that only 1% of seropositive individuals develop eye disease. The most common ocular manifestation of HSV is...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental optometry 2021-04, Vol.104 (3), p.396-405
Main Authors: Arshad, Sana, Petsoglou, Constantinos, Lee, Taehwan, Al-Tamimi, Abdullah, Carnt, Nicole A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1838-e522b9a743c742294a15f2b0812c2756913db29a8f8f3103640496f8f7e2f0ca3
cites cdi_FETCH-LOGICAL-c1838-e522b9a743c742294a15f2b0812c2756913db29a8f8f3103640496f8f7e2f0ca3
container_end_page 405
container_issue 3
container_start_page 396
container_title Clinical and experimental optometry
container_volume 104
creator Arshad, Sana
Petsoglou, Constantinos
Lee, Taehwan
Al-Tamimi, Abdullah
Carnt, Nicole A.
description Herpes Simplex Virus (HSV) is the most common virus that causes eye disease. Although around 60% of the world's population are seropositive for HSV antigens, fortunately, it is estimated that only 1% of seropositive individuals develop eye disease. The most common ocular manifestation of HSV is keratitis, while uveitis and retinal necrosis occur in a small number of cases. HSV keratitis is a debilitating disease, for several reasons: pain , photophobia, and vision loss in acute disease, latency of the virus which leads to infection reactivation from various triggers, scarring, and neovascularisation, leading to permanent vision loss with poor visual rehabilitation prospects. The Herpetic Eye Disease Study (HEDS) was a landmark series of randomised controlled trials in the 1990s that set the benchmark for evidence-based treatment guidelines for anterior eye herpetic disease. Since this time, there has been a change in the distribution of seroprevalence of herpes in the community, a simplified diagnostic classification, advances in treatment options, an emergence of new and a better understanding of risk factors, and discoveries in science that show promise for vaccine and novel future treatments. However, many of the principles of the HEDS study remain rightly entrenched in clinical practice. In this article, the HEDS study is revisited 20 years on through the lens of published literature, to determine current best practise and look towards the future.
doi_str_mv 10.1080/08164622.2021.1877531
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_08164622_2021_1877531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2666415178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1838-e522b9a743c742294a15f2b0812c2756913db29a8f8f3103640496f8f7e2f0ca3</originalsourceid><addsrcrecordid>eNp9kN1LwzAUxYMoOKd_ghDw1c58tU19Uub8gIEPzueQpbeY0SU16Rz9703ZfPXpcrjnnMv9IXRNyYwSSe6IpIUoGJsxwuiMyrLMOT1BEyqEyEjF5SmajJ5sNJ2jixg3hDDBKzFBbrUH1w94AB0ijtYZwP0X4FcIHfTW4MUA-MlG0BHwR7-rh3u8hBi9i7e4hh9ofbdNDRFrV2Pdda01urdpjXuPTWtd0i3ugjapDS7RWaPbCFfHOUWfz4vV_DVbvr-8zR-XmaGSywxyxtaVLgU3pWCsEprmDVunJ5hhZV5UlNdrVmnZyIZTwgtBRFUkUQJriNF8im4OvV3w3zuIvdr4XXDppGJFUQia01ImV35wmeBjDNCoLtitDoOiRI1o1R9aNaJVR7Qp93DIWdf4sNV7H9pa9XpofWiCdsZGxf-v-AUWw3-z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2666415178</pqid></control><display><type>article</type><title>Twenty years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Arshad, Sana ; Petsoglou, Constantinos ; Lee, Taehwan ; Al-Tamimi, Abdullah ; Carnt, Nicole A.</creator><creatorcontrib>Arshad, Sana ; Petsoglou, Constantinos ; Lee, Taehwan ; Al-Tamimi, Abdullah ; Carnt, Nicole A.</creatorcontrib><description>Herpes Simplex Virus (HSV) is the most common virus that causes eye disease. Although around 60% of the world's population are seropositive for HSV antigens, fortunately, it is estimated that only 1% of seropositive individuals develop eye disease. The most common ocular manifestation of HSV is keratitis, while uveitis and retinal necrosis occur in a small number of cases. HSV keratitis is a debilitating disease, for several reasons: pain , photophobia, and vision loss in acute disease, latency of the virus which leads to infection reactivation from various triggers, scarring, and neovascularisation, leading to permanent vision loss with poor visual rehabilitation prospects. The Herpetic Eye Disease Study (HEDS) was a landmark series of randomised controlled trials in the 1990s that set the benchmark for evidence-based treatment guidelines for anterior eye herpetic disease. Since this time, there has been a change in the distribution of seroprevalence of herpes in the community, a simplified diagnostic classification, advances in treatment options, an emergence of new and a better understanding of risk factors, and discoveries in science that show promise for vaccine and novel future treatments. However, many of the principles of the HEDS study remain rightly entrenched in clinical practice. In this article, the HEDS study is revisited 20 years on through the lens of published literature, to determine current best practise and look towards the future.</description><identifier>ISSN: 0816-4622</identifier><identifier>EISSN: 1444-0938</identifier><identifier>DOI: 10.1080/08164622.2021.1877531</identifier><language>eng</language><publisher>Chichester: Taylor &amp; Francis</publisher><subject>Antigens ; Clinical medicine ; Clinical trials ; Eye diseases ; Herpes simplex ; Herpes simplex keratitis ; herpes simplex virus ; Herpetic Eye Disease Study ; Keratitis ; Latency ; Rehabilitation ; Risk factors ; Serology ; Uveitis ; Viruses ; Vision</subject><ispartof>Clinical and experimental optometry, 2021-04, Vol.104 (3), p.396-405</ispartof><rights>2021 Optometry Australia 2021</rights><rights>2021 Optometry Australia</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1838-e522b9a743c742294a15f2b0812c2756913db29a8f8f3103640496f8f7e2f0ca3</citedby><cites>FETCH-LOGICAL-c1838-e522b9a743c742294a15f2b0812c2756913db29a8f8f3103640496f8f7e2f0ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Arshad, Sana</creatorcontrib><creatorcontrib>Petsoglou, Constantinos</creatorcontrib><creatorcontrib>Lee, Taehwan</creatorcontrib><creatorcontrib>Al-Tamimi, Abdullah</creatorcontrib><creatorcontrib>Carnt, Nicole A.</creatorcontrib><title>Twenty years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice</title><title>Clinical and experimental optometry</title><description>Herpes Simplex Virus (HSV) is the most common virus that causes eye disease. Although around 60% of the world's population are seropositive for HSV antigens, fortunately, it is estimated that only 1% of seropositive individuals develop eye disease. The most common ocular manifestation of HSV is keratitis, while uveitis and retinal necrosis occur in a small number of cases. HSV keratitis is a debilitating disease, for several reasons: pain , photophobia, and vision loss in acute disease, latency of the virus which leads to infection reactivation from various triggers, scarring, and neovascularisation, leading to permanent vision loss with poor visual rehabilitation prospects. The Herpetic Eye Disease Study (HEDS) was a landmark series of randomised controlled trials in the 1990s that set the benchmark for evidence-based treatment guidelines for anterior eye herpetic disease. Since this time, there has been a change in the distribution of seroprevalence of herpes in the community, a simplified diagnostic classification, advances in treatment options, an emergence of new and a better understanding of risk factors, and discoveries in science that show promise for vaccine and novel future treatments. However, many of the principles of the HEDS study remain rightly entrenched in clinical practice. In this article, the HEDS study is revisited 20 years on through the lens of published literature, to determine current best practise and look towards the future.</description><subject>Antigens</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Eye diseases</subject><subject>Herpes simplex</subject><subject>Herpes simplex keratitis</subject><subject>herpes simplex virus</subject><subject>Herpetic Eye Disease Study</subject><subject>Keratitis</subject><subject>Latency</subject><subject>Rehabilitation</subject><subject>Risk factors</subject><subject>Serology</subject><subject>Uveitis</subject><subject>Viruses</subject><subject>Vision</subject><issn>0816-4622</issn><issn>1444-0938</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kN1LwzAUxYMoOKd_ghDw1c58tU19Uub8gIEPzueQpbeY0SU16Rz9703ZfPXpcrjnnMv9IXRNyYwSSe6IpIUoGJsxwuiMyrLMOT1BEyqEyEjF5SmajJ5sNJ2jixg3hDDBKzFBbrUH1w94AB0ijtYZwP0X4FcIHfTW4MUA-MlG0BHwR7-rh3u8hBi9i7e4hh9ofbdNDRFrV2Pdda01urdpjXuPTWtd0i3ugjapDS7RWaPbCFfHOUWfz4vV_DVbvr-8zR-XmaGSywxyxtaVLgU3pWCsEprmDVunJ5hhZV5UlNdrVmnZyIZTwgtBRFUkUQJriNF8im4OvV3w3zuIvdr4XXDppGJFUQia01ImV35wmeBjDNCoLtitDoOiRI1o1R9aNaJVR7Qp93DIWdf4sNV7H9pa9XpofWiCdsZGxf-v-AUWw3-z</recordid><startdate>20210403</startdate><enddate>20210403</enddate><creator>Arshad, Sana</creator><creator>Petsoglou, Constantinos</creator><creator>Lee, Taehwan</creator><creator>Al-Tamimi, Abdullah</creator><creator>Carnt, Nicole A.</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>NAPCQ</scope></search><sort><creationdate>20210403</creationdate><title>Twenty years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice</title><author>Arshad, Sana ; Petsoglou, Constantinos ; Lee, Taehwan ; Al-Tamimi, Abdullah ; Carnt, Nicole A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1838-e522b9a743c742294a15f2b0812c2756913db29a8f8f3103640496f8f7e2f0ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Eye diseases</topic><topic>Herpes simplex</topic><topic>Herpes simplex keratitis</topic><topic>herpes simplex virus</topic><topic>Herpetic Eye Disease Study</topic><topic>Keratitis</topic><topic>Latency</topic><topic>Rehabilitation</topic><topic>Risk factors</topic><topic>Serology</topic><topic>Uveitis</topic><topic>Viruses</topic><topic>Vision</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arshad, Sana</creatorcontrib><creatorcontrib>Petsoglou, Constantinos</creatorcontrib><creatorcontrib>Lee, Taehwan</creatorcontrib><creatorcontrib>Al-Tamimi, Abdullah</creatorcontrib><creatorcontrib>Carnt, Nicole A.</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Clinical and experimental optometry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arshad, Sana</au><au>Petsoglou, Constantinos</au><au>Lee, Taehwan</au><au>Al-Tamimi, Abdullah</au><au>Carnt, Nicole A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Twenty years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice</atitle><jtitle>Clinical and experimental optometry</jtitle><date>2021-04-03</date><risdate>2021</risdate><volume>104</volume><issue>3</issue><spage>396</spage><epage>405</epage><pages>396-405</pages><issn>0816-4622</issn><eissn>1444-0938</eissn><abstract>Herpes Simplex Virus (HSV) is the most common virus that causes eye disease. Although around 60% of the world's population are seropositive for HSV antigens, fortunately, it is estimated that only 1% of seropositive individuals develop eye disease. The most common ocular manifestation of HSV is keratitis, while uveitis and retinal necrosis occur in a small number of cases. HSV keratitis is a debilitating disease, for several reasons: pain , photophobia, and vision loss in acute disease, latency of the virus which leads to infection reactivation from various triggers, scarring, and neovascularisation, leading to permanent vision loss with poor visual rehabilitation prospects. The Herpetic Eye Disease Study (HEDS) was a landmark series of randomised controlled trials in the 1990s that set the benchmark for evidence-based treatment guidelines for anterior eye herpetic disease. Since this time, there has been a change in the distribution of seroprevalence of herpes in the community, a simplified diagnostic classification, advances in treatment options, an emergence of new and a better understanding of risk factors, and discoveries in science that show promise for vaccine and novel future treatments. However, many of the principles of the HEDS study remain rightly entrenched in clinical practice. In this article, the HEDS study is revisited 20 years on through the lens of published literature, to determine current best practise and look towards the future.</abstract><cop>Chichester</cop><pub>Taylor &amp; Francis</pub><doi>10.1080/08164622.2021.1877531</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0816-4622
ispartof Clinical and experimental optometry, 2021-04, Vol.104 (3), p.396-405
issn 0816-4622
1444-0938
language eng
recordid cdi_crossref_primary_10_1080_08164622_2021_1877531
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Antigens
Clinical medicine
Clinical trials
Eye diseases
Herpes simplex
Herpes simplex keratitis
herpes simplex virus
Herpetic Eye Disease Study
Keratitis
Latency
Rehabilitation
Risk factors
Serology
Uveitis
Viruses
Vision
title Twenty years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T18%3A28%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Twenty%20years%20since%20the%20Herpetic%20Eye%20Disease%20Study:%20Lessons,%20developments%20and%20applications%20to%20clinical%20practice&rft.jtitle=Clinical%20and%20experimental%20optometry&rft.au=Arshad,%20Sana&rft.date=2021-04-03&rft.volume=104&rft.issue=3&rft.spage=396&rft.epage=405&rft.pages=396-405&rft.issn=0816-4622&rft.eissn=1444-0938&rft_id=info:doi/10.1080/08164622.2021.1877531&rft_dat=%3Cproquest_cross%3E2666415178%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1838-e522b9a743c742294a15f2b0812c2756913db29a8f8f3103640496f8f7e2f0ca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2666415178&rft_id=info:pmid/&rfr_iscdi=true